TITLE

Combo therapy

PUB. DATE
May 1996
SOURCE
Drug Topics;5/20/96, Vol. 140 Issue 10, p20
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Hoffman-La Roche and Abbott are conducting a clinical trial to assess the safety of concurrent therapy with the companies' drugs Invirase and Norvir for treatment of AIDS.
ACCESSION #
9612102692

 

Related Articles

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • Life Science Briefs.  // Chemical Market Reporter;03/20/2000, Vol. 257 Issue 12, p19 

    Presents news briefs on life science worldwide as of March 20, 2000. Agreement between Abbott Laboratories and the United States Federal Trade Commission on the marketing of generic terazosin hydrochloride; Appointment of David G. Eller as executive vice-president and president of DuPont...

  • Abbott to collaborate with Genentech, Roche and OSI on cancer drug test.  // PharmaWatch: Cancer;Apr2008, Vol. 7 Issue 4, p14 

    The article reports on the business agreement between Abbott Laboratories Inc., Genentech Inc., Hoffmann-La Roche Inc. and OSI Pharmaceuticals Inc. The agreement is designed for the development of a gene test to assess the clinical benefits of Tarceva, a lung cancer drug. Abbott is tasked to...

  • Pharmacy care Kit available from Roche.  // Drug Topics;10/10/94, Vol. 138 Issue 19, p8 

    Reports on the availability of a pharmacy counseling service from Roche Laboratories for patients on Roferon-A therapy.

  • Toradol labeling changed.  // Drug Topics;3/6/95, Vol. 139 Issue 5, p8 

    Reports on Roche Laboratories decision to change the labeling on its Toradol prescription pain reliever due to reports on side effects from improper use. Usage of the drug for pain management in postsurgical patients.

  • Program prevents pregnancies during tx.  // Dermatology Times;Sep95, Vol. 16 Issue 9, p3 

    Reports on the pregnancy prevention program conducted by Hoffman-La Roche Inc. during isotretinoin treatment for its patients.

  • La Roche lottery.  // Northern New Jersey Business;6/28/95, Vol. 3 Issue 13, p3 

    Reports on the US Food and Drug Administration's approval of the drug called Invirase, manufactured by Hoffman-La Roche.

  • Roche cuts controversial PCR fees, testing limits. Anderson, C. // Nature;1/30/1992, Vol. 355 Issue 6359, p379 

    Reports that Swiss-owned pharmaceutical company Hoffmann-La Roche, under pressure from researchers and diagnostic companies, agreed to lower its prices on its polymerase chain reaction (PCR) technology and lift restrictions on its use. The move should free the technology for widespread use in...

  • Licences sought from PCR users in Britain. Dickson, David // Nature;1/28/1993, Vol. 361 Issue 6410, p291 

    Reports that genetic-screening devices throughout Britain could have their costs increase significantly as a result of claims for royalties on one of the basic laboratory techniques used in diagnostic testing, polymerase chain reaction (PCR). Recent granting of two patents on the PCR process by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics